DOCSLIB.ORG

Pharmaceutical Appendix to the Tariff Schedule 2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmaceutical Appendix to the Tariff Schedule 2 Harmonized Tariff Schedule of the United States (2004) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACETYLCHOLINE CHLORIDE 60-31-1 ABAFUNGIN 129639-79-8 ACETYLCYSTEINE 616-91-1 ABAMECTIN 65195-55-3 ACETYLDIGITOXIN 1111-39-3 ABANOQUIL 90402-40-7 ACETYLLEUCINE 99-15-0 ABARELIX 183552-38-7 ACETYLMETHADOL 509-74-0 ABCIXIMAB 143653-53-6 ACEVALTRATE 25161-41-5 ABECARNIL 111841-85-1 ACEXAMIC ACID 57-08-9 ABIRATERONE 154229-19-3 ACICLOVIR 59277-89-3 ABITESARTAN 137882-98-5 ACIFRAN 72420-38-3 ABLUKAST 96566-25-5 ACIPIMOX 51037-30-0 ABUNIDAZOLE 91017-58-2 ACITAZANOLAST 114607-46-4 ACADESINE 2627-69-2 ACITEMATE 101197-99-3 ACAMPROSATE 77337-76-9 ACITRETIN 55079-83-9 ACAPRAZINE 55485-20-6 ACIVICIN 42228-92-2 ACARBOSE 56180-94-0 ACLANTATE 39633-62-0 ACEBROCHOL 514-50-1 ACLARUBICIN 57576-44-0 ACEBURIC ACID 26976-72-7 ACLATONIUM NAPADISILATE 55077-30-0 ACEBUTOLOL 37517-30-9 ACODAZOLE 79152-85-5 ACECAINIDE 32795-44-1 ACONIAZIDE 13410-86-1 ACECARBROMAL 77-66-7 ACOXATRINE 748-44-7 ACECLIDINE 827-61-2 ACREOZAST 123548-56-1 ACECLOFENAC 89796-99-6 ACRIDOREX 47487-22-9 ACEDAPSONE 77-46-3 ACRIFLAVINIUM CHLORIDE 8063-24-9 ACEDIASULFONE SODIUM 127-60-6 ACRIHELLIN 67696-82-6 ACEDOBEN 556-08-1 ACRISORCIN 7527-91-5 ACEFLURANOL 80595-73-9 ACRIVASTINE 87848-99-5 ACEFURTIAMINE 10072-48-7 ACROCINONIDE 28971-58-6 ACEFYLLINE PIPERAZINE 18428-63-2 ACRONINE 7008-42-6 ACEFYLLINE CLOFIBROL 70788-27-1 ACTAGARDIN ACEGLATONE 642-83-1 ACTAPLANIN 37305-75-2 ACEGLUTAMIDE 2490-97-3 ACTARIT 18699-02-0 ACEMANNAN 110042-95-0 ACTINOQUINOL 15301-40-3 ACEMETACIN 53164-05-9 ACTISOMIDE 96914-39-5 ACENEURAMIC ACID 131-48-6 ACTODIGIN 36983-69-4 ACENOCOUMAROL 152-72-7 ADAFENOXATE 82168-26-1 ACEPERONE 807-31-8 ADAMEXINE 54785-02-3 ACEPROMAZINE 61-00-7 ADAPALENE 106685-40-9 ACEPROMETAZINE 13461-01-3 ADAPROLOL 101479-70-3 ACEQUINOLINE 42465-20-3 ADATANSERIN 127266-56-2 ACESULFAME 33665-90-6 ADEFOVIR 106941-25-7 ACETAMINOSALOL 118-57-0 ADELMIDROL 1675-66-7 ACETARSOL 97-44-9 ADEMETIONINE 17176-17-9 ACETAZOLAMIDE 59-66-5 ADENOSINE PHOSPHATE 61-19-8 ACETERGAMINE 3031-48-9 ADIBENDAN 100510-33-6 ACETIAMINE 299-89-8 ADICILLIN 525-94-0 ACETIROMATE 2260-08-4 ADIMOLOL 78459-19-5 ACETOHEXAMIDE 968-81-0 ADINAZOLAM 37115-32-5 ACETOHYDROXAMIC ACID 546-88-3 ADIPHENINE 64-95-9 ACETOPHENAZINE 2751-68-0 ADIPIODONE 606-17-7 ACETORPHINE 25333-77-1 ADITEREN 56066-19-4 ACETRYPTINE 3551-18-6 ADITOPRIM 56066-63-8 Harmonized Tariff Schedule of the United States (2004) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Product CAS No. Product CAS No. ADOSOPINE 88124-26-9 ALLOCLAMIDE 5486-77-1 ADOZELESIN 110314-48-2 ALLOCUPREIDE SODIUM 5965-40-2 ADRAFINIL 63547-13-7 ALLOMETHADIONE 526-35-2 ADRENALONE 99-45-6 ALLOPURINOL 315-30-0 AFALANINE 2901-75-9 ALLYLESTRENOL 432-60-0 AFELIMOMAB 156227-98-4 ALLYLPRODINE 25384-17-2 AFLOQUALONE 56287-74-2 ALLYLTHIOUREA 109-57-9 AFOVIRSEN 151356-08-0 ALMADRATE SULFATE 60239-66-9 AFUROLOL 65776-67-2 ALMAGATE 66827-12-1 AGANODINE 86696-87-9 ALMAGODRATE AGLEPRISTONE 124478-60-0 ALMASILATE 71205-22-6 AGOMELATINE 138112-76-2 ALMECILLIN 87-09-2 AKLOMIDE 3011-89-0 ALMESTRONE 10448-96-1 ALACEPRIL 74258-86-9 ALMINOPROFEN 39718-89-3 ALAFOSFALIN 60668-24-8 ALMITRINE 27469-53-0 ALANINE 56-41-7 ALMOKALANT 123955-10-2 ALANOSINE 5854-93-3 ALMOTRIPTAN 154323-57-6 ALAPROCLATE 60719-82-6 ALMOXATONE 84145-89-1 ALATROFLOXACIN 157182-32-6 ALMURTIDE 61136-12-7 ALAZANINE TRICLOFENATE 5779-59-9 ALNESPIRONE 138298-79-0 ALBENDAZOLE 54965-21-8 ALNIDITAN 152317-89-0 ALBENDAZOLE OXIDE 54029-12-8 ALONACIC 105292-70-4 ALBIFYLLINE 107767-55-5 ALONIMID 2897-83-8 ALBUTOIN 830-89-7 ALORACETAM 119610-26-3 ALCLOFENAC 22131-79-9 ALOSETRON 122852-42-0 ALCLOMETASONE 67452-97-5 ALOVUDINE 25526-93-6 ALCLOXA 1317-25-5 ALOXIPRIN 9014-67-9 ALCURONIUM CHLORIDE 15180-03-7 ALOXISTATIN 88321-09-9 ALDESULFONE SODIUM 144-75-2 ALOZAFONE 65899-72-1 ALDIOXA 5579-81-7 ALPERTINE 27076-46-6 ALDOSTERONE 52-39-1 ALPHACETYLMETHADOL 17199-58-5 ALENDRONIC ACID 66376-36-1 ALPHAMEPRODINE 468-51-9 ALENTEMOL 112891-97-1 ALPHAMETHADOL 17199-54-1 ALEPRIDE 66564-15-6 ALPHAPRODINE 77-20-3 ALESTRAMUSTINE 139402-18-9 ALPIDEM 82626-01-5 ALEXIDINE 22573-93-9 ALPIROPRIDE 81982-32-3 ALEXITOL SODIUM 66813-51-2 ALPRAFENONE 124316-02-5 ALFACALCIDOL 41294-56-8 ALPRAZOLAM 28981-97-7 ALFADEX 10016-20-3 ALPRENOLOL 13655-52-2 ALFADOLONE 14107-37-0 ALPROSTADIL 745-65-3 ALFAPROSTOL 74176-31-1 ALRESTATIN 51411-04-2 ALFAXALONE 23930-19-0 ALSACTIDE 34765-96-3 ALFENTANIL 71195-58-9 ALTANSERIN 76330-71-7 ALFETAMINE 4255-23-6 ALTAPIZONE 93277-96-4 ALFUZOSIN 81403-80-7 ALTECONAZOLE 93479-96-0 ALGELDRATE 1330-44-5 ALTEPLASE 105857-23-6 ALGESTONE 595-77-7 ALTIZIDE 5588-16-9 ALGLUCERASE 143003-46-7 ALTOQUALINE 121029-11-6 ALIBENDOL 26750-81-2 ALTRENOGEST 850-52-2 ALICONAZOLE 63824-12-4 ALTRETAMINE 645-05-6 ALIFEDRINE 78756-61-3 ALTUMOMAB 156586-92-4 ALIFLURANE 56689-41-9 ALUMINIUM CLOFIBRATE 24818-79-9 ALIMADOL 52742-40-2 ALUSULF 61115-28-4 ALIMEMAZINE 84-96-8 ALVERINE 150-59-4 ALINASTINE 154541-72-7 ALVIRCEPT SUDOTOX 137487-62-8 ALINIDINE 33178-86-8 AMADINONE 30781-27-2 ALIPAMIDE 3184-59-6 AMAFOLONE 50588-47-1 ALIZAPRIDE 59338-93-1 AMANOZINE 537-17-7 ALLETORPHINE 23758-80-7 AMANTADINE 768-94-5 ALLOBARBITAL 52-43-7 AMANTANIUM BROMIDE 58158-77-3 Harmonized Tariff Schedule of the United States (2004) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 4 Product CAS No. Product CAS No. AMANTOCILLIN 10004-67-8 AMINOQUINOL 10023-54-8 AMBAMUSTINE 85754-59-2 AMINOQUINURIDE 3811-56-1 AMBASILIDE 83991-25-7 AMINOREX 2207-50-3 AMBAZONE 539-21-9 AMINOTHIAZOLE 96-50-4 AMBENONIUM CHLORIDE 115-79-7 AMINOXYTRIPHENE 5585-64-8 AMBENOXAN 2455-84-7 AMIODARONE 1951-25-3 AMBICROMIL 58805-38-2 AMIPERONE 1580-71-8 AMBOMYCIN 1402-81-9 AMIPHENAZOLE 490-55-1 AMBROXOL 18683-91-5 AMIPIZONE 69635-63-8 AMBRUTICIN 58857-02-6 AMIPRILOSE 56824-20-5 AMBUCAINE 119-29-9 AMIQUINSIN 13425-92-8 AMBUCETAMIDE 519-88-0 AMISOMETRADINE 550-28-7 AMBUSIDE 3754-19-6 AMISULPRIDE 71675-85-9 AMCINAFAL 3924-70-7 AMITEROL 54063-25-1 AMCINAFIDE 7332-27-6 AMITIVIR 111393-84-1 AMCINONIDE 51022-69-6 AMITRAZ 33089-61-1 AMEBUCORT 83625-35-8 AMITRIPTYLINE 50-48-6 AMEDALIN 22136-26-1 AMITRIPTYLINOXIDE 4317-14-0 AMELOMETASONE 123013-22-9 AMIXETRINE 24622-72-8 AMELTOLIDE 787-93-9 AMLEXANOX 68302-57-8 AMESERGIDE 121588-75-8 AMLINTIDE 122384-88-7 AMETANTRONE 64862-96-0 AMLODIPINE 88150-42-9 AMEZEPINE 60575-32-8 AMOBARBITAL 57-43-2 AMEZINIUM METILSULFATE 30578-37-1 AMOCARZINE 36590-19-9 AMFEBUTAMONE 34911-55-2 AMODIAQUINE 86-42-0 AMFECLORAL 5581-35-1 AMOGASTRIN 16870-37-4 AMFENAC 51579-82-9 AMOLANONE 76-65-3 AMFEPENTOREX 15686-27-8 AMONAFIDE 69408-81-7 AMFEPRAMONE 90-84-6 AMOPROXAN 22661-76-3 AMFETAMINE 300-62-9 AMOPYROQUINE 550-81-2 AMFETAMINIL 17590-01-1 AMOROLFINE 78613-35-1 AMFLUTIZOLE 82114-19-0 AMOSCANATE 26328-53-0 AMFOMYCIN 1402-82-0 AMOSULALOL 85320-68-9 AMFONELIC ACID 15180-02-6 AMOXAPINE 14028-44-5 AMICARBALIDE 3459-96-9 AMOXECAINE 553-65-1 AMICIBONE 23271-63-8 AMOXICILLIN 26787-78-0 AMICYCLINE 5874-95-3 AMOXYDRAMINE CAMSILATE 15350-99-9 AMIDANTEL 49745-00-8 AMPEROZIDE 75558-90-6 AMIDAPSONE 3569-77-5 AMPHENIDONE 134-37-2 AMIDEFRINE MESILATE 1421-68-7 AMPHOTALIDE 1673-06-9 AMIFLAMINE 77518-07-1 AMPHOTERICIN B 1397-89-3 AMIFLOVERINE 54063-24-0 AMPICILLIN 69-53-4 AMIFLOXACIN 86393-37-5 AMPIROXICAM 99464-64-9 AMIFOSTINE 20537-88-6 AMPROLIUM 121-25-5 AMIKACIN 37517-28-5 AMPYRIMINE 5587-93-9 AMIKHELLINE 4439-67-2 AMPYZINE 5214-29-9 AMILORIDE 2609-46-3 AMQUINATE 17230-85-2 AMINDOCATE 31386-24-0 AMRINONE 60719-84-8 AMINEPTINE 57574-09-1 AMRUBICIN 110267-81-7 AMINITROZOLE 140-40-9 AMSACRINE 51264-14-3 AMINOACRIDINE 90-45-9 AMTOLMETIN GUACIL 87344-06-7 AMINOCAPROIC ACID 60-32-2 AMYLMETACRESOL 1300-94-3 AMINOETHYL NITRATE 646-02-6 ANAGESTONE 2740-52-5 AMINOGLUTETHIMIDE 125-84-8 ANAGRELIDE 68475-42-3 AMINOMETRADINE 642-44-4 ANAKINRA 143090-92-0 AMINOPHENAZONE 58-15-1 ANARITIDE 95896-08-5 AMINOPHENAZONE CYCLAMATE 747-30-8 ANASTROZOLE 120511-73-1 AMINOPHYLLINE 317-34-0 ANAXIRONE 77658-97-0 AMINOPROMAZINE 58-37-7 ANAZOCINE 15378-99-1 AMINOPTERIN SODIUM 58602-66-7 ANAZOLENE SODIUM 3861-73-2 Harmonized Tariff Schedule of the United States (2004) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 5 Product CAS No. Product CAS No. ANCAROLOL 75748-50-4 ARGIMESNA 106854-46-0 ANCITABINE 31698-14-3 ARGININE 74-79-3 ANCROD 9046-56-4 ARGIPRESSIN 113-79-1 ANDOLAST 132640-22-3 ARGIPRESTOCIN 113-80-4 ANDROSTANOLONE 521-18-6 ARILDONE 56219-57-9 ANGIOTENSIN II 4474-91-3 ARIPIPRAZOLE 129722-12-9 ANGIOTENSINAMIDE 53-73-6 ARNOLOL 87129-71-3 ANIDOXIME 34297-34-2 ARONIXIL 86627-15-8 ANILAMATE 5591-49-1 AROFYLLINE 136145-07-8 ANILERIDINE 144-14-9 AROTINOLOL 68377-92-4 ANILOPAM 53716-46-4 ARPRINOCID 55779-18-5 ANIPAMIL 83200-10-6 ARPROMIDINE 106669-71-0 ANIRACETAM 72432-10-1 ARSANILIC ACID 98-50-0 ANIROLAC 66635-85-6
Load more

Recommended publications
  • Automated Annotation of Structurally Uncharacterized Metabolites in Human Metabolomics Studies by Systems Biology Models
    Technische Universität München Automated annotation of structurally uncharacterized metabolites in human metabolomics studies by systems biology models Jan-Dominik Bernd Quell 2019 Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt Technische Universität München Lehrstuhl für Experimentelle Bioinformatik Automated annotation of structurally uncharacterized metabo- lites in human metabolomics studies by systems biology models Jan-Dominik Bernd Quell Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Er- nährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) genehmigten Dissertation. Vorsitzender: Prof. Dr. Dmitrij Frischmann Prüfer der Dissertation: 1. Prof. Dr. Hans-Werner Mewes 2. Prof. Dr. Bernhard Küster Die Dissertation wurde am 28.11.2018 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 28.01.2019 angenommen. „Der Mensch muß bei dem Glauben verharren, daß das Unbegreifliche begreiflich sei; er würde sonst nicht forschen.“ Johann Wolfgang von Goethe i Danksagung Zunächst möchte ich mich ganz besonders bei meinem Doktorvater (Hans-)Werner Mewes bedanken, der mir nicht nur die Möglichkeit gegeben hat an seinem Institut des Helmholtz Zentrums München sowie seinem Lehrstuhl an der Technischen Uni- versität München in Forschung und Lehre zu arbeiten, sondern auch meine Laufbahn
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • Title Effects of N-Acetyl-Leucine and Its Enantiomers in Niemann-Pick
    bioRxiv preprint doi: https://doi.org/10.1101/826222; this version posted October 31, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title Effects of N-Acetyl-Leucine and its enantiomers in Niemann-Pick disease type C cells Danielle te Vruchte1, Anthony Galione2, Michael Strupp3 and Michiko Mann1 1IntraBio Ltd, Oxford University Begbroke Science Park, Woodstock Road, Oxford, UK 2Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, UK 3Department of Neurology and German Center for Vertigo and Balance Disorders, Ludwig Maximilians University, Munich, Germany Corresponding author Danielle te Vruchte Email: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/826222; this version posted October 31, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Conflicts of Interest A.G. is a cofounder, shareholder and consultant to IntraBio. M.Y-M and D.t.V. are shareholders in IntraBio. M.S. acts as a consultant for Abbott, Actelion, AurisMedical, Heel, IntraBio and Sensorion, is a shareholder of IntraBio and Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. M.S. has received speaker’s honoraria from Abbott, Actelion, Auris Medical, Biogen, Eisai, Grunenthal, GSK, Henning Pharma, Interacoustics, Merck, MSD, Otometrics, Pierre-Fabre, TEVA, UCB. bioRxiv preprint doi: https://doi.org/10.1101/826222; this version posted October 31, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • Guaiana, G., Barbui, C., Caldwell, DM, Davies, SJC, Furukawa, TA
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Explore Bristol Research Guaiana, G., Barbui, C., Caldwell, D. M., Davies, S. J. C., Furukawa, T. A., Imai, H., ... Cipriani, A. (2017). Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews, 2017(7), [CD012729]. https://doi.org/10.1002/14651858.CD012729 Publisher's PDF, also known as Version of record Link to published version (if available): 10.1002/14651858.CD012729 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Cochrane Library at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012729/full . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms Cochrane Database of Systematic Reviews Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis (Protocol) Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A. Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews 2017, Issue 7.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • Neurobiological and Neurobehavioral Mechanisms of Chronic Alcohol Drinking
    Neurobiological and Neurobehavioral Mechanisms of Chronic Alcohol Drinking Neurobiological and Neurobehavioral Mechanisms of Chronic Alcohol Drinking Alcoholism comprises a set of complex behaviors seeking behaviors, have been developed. These in which an individual becomes increasingly models, which remain an integral part of the preoccupied with obtaining alcohol. These study of alcoholism, include animals that pref- behaviors ultimately lead to a loss of control over erentially drink solutions containing alcohol, consumption of the drug and to the development animals that self-administer alcohol during of tolerance, dependence, and impaired social and withdrawal, animals with a history of dependence occupational functioning. that self-administer alcohol, and animals that self- administer alcohol after a period of abstinence Although valuable information regarding toler- from the drug. Genetic models for alcoholism ance and dependence has been, and continues to also exist and include animals that have been bred be, gathered through human studies, much of the selectively for high alcohol consumption. Studies detailed understanding of the impact of exposure using such models are uncovering the systemic, to alcohol on behavior and on the biological cellular, and molecular neurobiological mech- mechanisms underlying those behaviors has been anisms that appear to contribute to chronic obtained through the use of animal models for alcohol consumption. The challenge of current alcoholism and a variety of in vitro, or cellular, and future studies is to understand which specific systems. Through the use of cellular systems and cellular and subcellular systems undergo mole- animal models, researchers can control the genetic cular changes to influence tolerance and depen- background and experimental conditions under dence in motivational systems that lead to which a specific alcohol-related behavior or chronic drinking.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Alfadolone Acetate (BANM, Rinnm) 362: 1749–57
    1780 General Anaesthetics blood, then to the brain; recovery is a function of the zolam, and other anaesthetics such as etomidate, propofol, ful if the patient’s cooperation is required, as conscious- removal of the anaesthetic from the brain. With inject- or ketamine. Small doses of short-acting opioids, for ex- ness soon returns once the nitrous oxide is stopped. The able anaesthetics their activity is similarly dependent ample alfentanil, fentanyl, or remifentanil, given before or neuroleptic most commonly employed was droperidol and on their ability to penetrate the blood/brain barrier and at induction allow the use of smaller induction doses of it was usually used with fentanyl although other opioids recovery in turn is governed by their redistribution and some drugs used for anaesthesia, and this technique is par- have also been used. These procedures have since evolved ticularly suitable for poor-risk patients. into conscious sedation and monitored anaesthetic care excretion. The potency of inhalational anaesthetics is After induction, muscle relaxation with a rapidly acting techniques employing newer drugs. often expressed in terms of minimum alveolar concen- depolarising neuromuscular blocker such as suxamethoni- Ketamine used alone can produce a state of dissociative trations, known as MAC values. The MAC of an um aids intubation of the patient. Longer acting, compet- anaesthesia similar to that of neuroleptanalgesia in which anaesthetic is the concentration at 1 atmosphere that itive neuromuscular blockers may then be given to allow the patient may appear to be awake but is unconscious. will produce immobility in 50% of subjects exposed to procedures such as abdominal surgery to be carried out un- Marked analgesia and amnesia are produced, but there a noxious stimulus.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]